InMode (NASDAQ:INMD - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, April 28th. Analysts expect InMode to post earnings of $0.45 per share and revenue of $82.21 million for the quarter.
InMode Stock Performance
Shares of INMD stock traded down $0.05 during mid-day trading on Wednesday, hitting $15.58. The company's stock had a trading volume of 1,259,668 shares, compared to its average volume of 1,173,556. InMode has a 52-week low of $13.68 and a 52-week high of $19.85. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of 6.63 and a beta of 1.96. The business has a 50-day moving average price of $17.47 and a 200 day moving average price of $17.60.
Analyst Ratings Changes
INMD has been the topic of several research analyst reports. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Wednesday, April 9th. Jefferies Financial Group lowered their price objective on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Finally, Barclays lifted their target price on shares of InMode from $26.00 to $29.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $21.25.
Read Our Latest Analysis on InMode
About InMode
(
Get Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Further Reading
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
